Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Range Nuclear Renaissance ETF (NUKZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Range Nuclear Renaissance ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Range Nuclear Renaissance ETF trades at $58.42 (market cap $662.96M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Range Nuclear Renaissance ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Range Nuclear Renaissance ETF for 23 Days on average.
| MRVI | NUKZ | |
|---|---|---|
Market Cap | $977.37M | $662.96M |
Volume | 2,742,564 | 99,094 |
Sector | Health | Sector/Thematic |
52-Week High | $9.00 | $76.23 |
52-Week Low | $2.83 | $58.42 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
NUKZ (Range Nuclear Renaissance Index ETF) trades at $60.37, showing minimal daily movement (+0.18%). The technical picture remains bearish with moving averages signaling strong selling pressure, though oscillators suggest neutral momentum. Recent industry developments include Google's 3.6 GW nuclear deal with Constellation Energy and record global nuclear power generation, creating positive sector tailwinds despite the ETF's current technical weakness.
The nuclear energy sector faces both significant catalysts and challenges. Strong demand from AI data centers and federal support for new projects provide growth opportunities, while supply chain bottlenecks and execution risks remain concerns. With the ETF trading near support levels, investors are watching for fundamental improvements to drive price recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Range Nuclear Renaissance ETF
Range Nuclear Renaissance ETF seeks to track companies related to the nuclear energy industry. Its holdings may include businesses involved in uranium, nuclear power generation, reactors, and nuclear services.
Read more on NUKZ →
